Credit Suisse’s Five Prime Therapeutics, Inc. FPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-254,090
| Closed | -$9.57M | – | 4765 |
|
|
2021
Q1 | $9.57M | Buy |
254,090
+233,124
| +1,112% | +$5.81M | ﹤0.01% | 1614 |
|
|
2020
Q4 | $357K | Buy |
+20,966
| New | +$263K | ﹤0.01% | 3922 |
|
|
2019
Q4 | – | Sell |
-24,513
| Closed | -$95K | – | 4411 |
|
|
2019
Q3 | $95K | Sell |
24,513
-7,849
| -24% | -$43.1K | ﹤0.01% | 3975 |
|
|
2019
Q2 | $195K | Buy |
32,362
+6,406
| +25% | +$61.2K | ﹤0.01% | 3847 |
|
|
2019
Q1 | $349K | Sell |
25,956
-1,831
| -7% | -$20.9K | ﹤0.01% | 3533 |
|
|
2018
Q4 | $258K | Buy |
27,787
+4,666
| +20% | +$55.5K | ﹤0.01% | 3580 |
|
|
2018
Q3 | $321K | Sell |
23,121
-18,508
| -44% | -$275K | ﹤0.01% | 3490 |
|
|
2018
Q2 | $658K | Sell |
41,629
-4,810
| -10% | -$83.9K | ﹤0.01% | 3287 |
|
|
2018
Q1 | $798K | Buy |
46,439
+10,526
| +29% | +$205K | ﹤0.01% | 3108 |
|
|
2017
Q4 | $786K | Sell |
35,913
-51,214
| -59% | -$1.65M | ﹤0.01% | 3164 |
|
|
2017
Q3 | $3.57M | Sell |
87,127
-2,044
| -2% | -$64.2K | ﹤0.01% | 2046 |
|
|
2017
Q2 | $2.69M | Sell |
89,171
-18,622
| -17% | -$581K | ﹤0.01% | 2037 |
|
|
2017
Q1 | $3.9M | Buy |
107,793
+31,740
| +42% | +$1.4M | ﹤0.01% | 1833 |
|
|
2016
Q4 | $3.81M | Sell |
76,053
-643
| -0.8% | -$33.8K | ﹤0.01% | 1864 |
|
|
2016
Q3 | $4.03M | Buy |
76,696
+12,325
| +19% | +$589K | ﹤0.01% | 1827 |
|
|
2016
Q2 | $2.66M | Buy |
64,371
+4,352
| +7% | +$189K | ﹤0.01% | 2117 |
|
|
2016
Q1 | $2.44M | Buy |
60,019
+51,067
| +570% | +$1.76M | ﹤0.01% | 2053 |
|
|
2015
Q4 | $371K | Sell |
8,952
-4,572
| -34% | -$153K | ﹤0.01% | 3570 |
|
|
2015
Q3 | $208K | Sell |
13,524
-45,073
| -77% | -$969K | ﹤0.01% | 3910 |
|
|
2015
Q2 | $1.46M | Buy |
58,597
+17,807
| +44% | +$397K | ﹤0.01% | 2831 |
|
|
2015
Q1 | $932K | Buy |
40,790
+21,753
| +114% | +$549K | ﹤0.01% | 3029 |
|
|
2014
Q4 | $514K | Buy |
+19,037
| New | +$328K | ﹤0.01% | 3692 |
|
Credit Suisse's FPRX Position: Q2 2021 in Review
Credit Suisse sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2021, closing a stake of 254,090 shares — an estimated $9.57M sold.
Credit Suisse first reported a position in FPRX in Q4 2014 and held it in 22 quarters. The position peaked at $9.57M in Q1 2021. 0 funds tracked by Wall St. Rank hold FPRX as of Q2 2021.
- Credit Suisse reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
- Credit Suisse sold 254,090 Five Prime Therapeutics, Inc. shares in Q2 2021, an estimated $9.57M.
- Credit Suisse first reported a position in Five Prime Therapeutics, Inc. in Q4 2014 and held it in 22 quarters.
- Credit Suisse's Five Prime Therapeutics, Inc. position peaked at $9.57M in Q1 2021.
- 0 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2021.
Based on Credit Suisse's 13F filing for Q2 2021, filed 16 Aug 2021.